Advertisement

Contact Person

Dr. Elinor Switzer

Managing Editor

Phone: +49 (0)711 - 2 29 87 63
Fax: +49 (0)711 - 2 29 87 65
send an Email


Archive

Recent developments in topical thrombins

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
DOI: http://dx.doi.org/10.1160/TH09-01-0034
Issue: 2009: 102/1 (July) pp. 1-183
Pages: 15-24

Recent developments in topical thrombins

Craig M. Kessler1; Thomas L. Ortel2
1Division of Coagulation, Department of Laboratory Medicine, Georgetown University, Washington, DC, USA; 2Hemostasis and Thrombosis Center, Duke University, Durham, North Carolina, USA

Keywords

thrombin, Haemostasis, coagulopathy, Bovine, Recombinant

Summary

Managing blood loss is part of the surgeon’s responsibility during surgical procedures, and a variety of therapeutic strategies are available to help accomplish this. Topical haemostatic agents are among the agents used to control surgical bleeding and locally arrest blood flow. Bovine thrombin is a commonly used topical haemostatic agent; however, its use has been associated with potential risks, including well-documented cases of antibodymediated coagulopathy. This coagulopathy develops as a consequence of antibody formation directed against bovine thrombin, other bovine coagulation proteins, and their human orthologs. The fact that a coagulopathy can result in association with the use of bovine plasma-derived thrombin preparations prompted the FDA to require pharmaceutical companies to place a blackbox warning in their prescribing information for products containing bovine plasma-derived thrombin. Recently, human plasma- derived thrombin and recombinant human thrombin have been approved by the FDA with the expectation that they will be less immunogenic than the bovine-derived product. In clinical studies, purified human plasma-derived thrombin and recombinant thrombin have demonstrated equivalent efficacy and safety, with improved immunogenicity profiles compared with bovinederived thrombin agents. Well-designed and adequately powered clinical trials should be conducted to indicate whether human thrombin products would improve the risk-benefit and costbenefit profiles for surgeries complicated by excessive bleeding.

You may also be interested in...

1.

Frederick A. Ofosu1, John Freedman2, John W. Semple2

Thromb Haemost 2008 99 5: 851-862

http://dx.doi.org/10.1160/TH07-10-0592

2.
Simone J. H. Wielders1; Jos Broers2; Hugo ten Cate3; Peter W. Collins4; Edouard M. Bevers1; Theo Lindhout1

Thromb Haemost 2009 102 1: 76-82

http://dx.doi.org/10.1160/TH08-11-0719

3.
K. G. Mann1; T. Orfeo1; S. Butenas1; A. Undas2; K. Brummel-Ziedins1

Hämostaseologie 2009 29 1: 7-16